This study is for people diagnosed with Acute Myeloid Leukemia (AML), a type of blood cancer. Researchers are looking at specific markers called CLL1 and CD45RA on certain blood cells (hematopoietic stem cells) during your initial AML treatment. They will measure the percentage of these cells on days 3, 5, and 7 of your therapy. The goal is to see if these markers can predict how well you respond to treatment after six weeks. This could help doctors choose the best treatments for AML patients more quickly, potentially avoiding invasive bone marrow biopsies. You can join if you are 18 or older, have AML, can receive treatment at the research center, and have elevated levels of CLL1A and CD45RA positive cells at diagnosis.

Study design

This is an observational study with a planned enrollment of 20 participants. It is not a drug trial but rather looks at specific markers in your blood.

What's involved

You would have blood samples taken on days 3, 5, and 7 during your initial AML treatment to measure specific cell markers.

Compensation

Not stated in the trial record.

Follow-up

Researchers will assess your treatment response at 6 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.